Abemaciclib, Abemaciclib-related Diarrhea, Breast Cancer
Conditions
Brief summary
Remarkable progress has recently been made in the treatment of locally advanced, hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence, thanks to the addition of abemaciclib to endocrine therapy. This combination has led to a significant improvement in invasive disease-free survival. However, despite the combination's acceptable safety profile, 38% of patients experience grade 3 or higher diarrhea, and 23% experience grade 3 or higher neutropenia. This toxicity can lead to the premature discontinuation of treatment, limiting the benefits of this molecule. As with all oral therapies, the pharmacokinetics of abemaciclib lie at the intersection of efficacy and toxicity and can be modified by several external factors. The hypothesis of the study is that abemaciclib's toxicity is correlated with its plasma levels and that its concentration is modified by certain patient characteristics. To this end, a pharmacokinetic model of abemaciclib could be developed using a prospective, multicenter, real-world blood dosage study. This study will describe the relationship between abemaciclib concentration and diarrhea and severe neutropenia, as classified by CTCAE, as well as potential clinical and drug interactions. It is hoped that this model demonstrates the importance of monitoring abemaciclib concentrations. This could lead to a therapeutic trial in which the abemaciclib dose is adjusted according to concentration to limit toxicity while maintaining efficacy.
Interventions
BIOLOGICALBlood samples for PK
Three additional blood tubes will be collected during routine biological tests.
OTHERQuestionnaire
EQ-5D-5L
Sponsors
Poitiers University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
pharmacokinetic model
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women ≥ 18 years old * Having breast cancer of all histologies combined * Type Luminal A or B with positive hormone receptors (\>10% expression for estrogen receptor and/or progesterone receptor) and HER2 negative or low epidermal growth receptor (according to GEFPICS1 definition) * Stage 2 or stage 3 according to the international classification, translated into the SENORIF recommendation * Having undergone complete excision surgery (R0 on the invasive tumor and/or on the ductal entity in situ) after neoadjuvant chemotherapy or not * Defined as high risk of recurrence according to the Monarch-E study, at initial diagnosis of the disease: either ≥ 4 affected axillary lymph nodes (≥N2 involvement), or 1-3 affected axillary lymph nodes (≥N1 involvement) associated with an Elston Ellis grade 3 or a tumor ≥ 5 cm * Initiation of adjuvant treatment with abemaciclib in combination with hormone therapy * Patient ECOG performance status between 0 and 2 * Patients with a neutrophil count (NCC) defined as normal prior to the first dose of abemaciclib, i.e., an absolute NCC ≥ 1500/ mm3 (≥ 1.5 x 109/L) without granulocyte colony-stimulating factor (GCSF) injection within 15 days prior to laboratory testing, as well as a platelet count ≥ 100,000/mm3 and a hemoglobin level ≥ 8g/dL. * Patient with the psychological and mental capacity to understand the protocol and sign the consent form independently * Must be affiliated with the social security system or receive benefits through a third party * Have signed the study consent form after reading the information sheet
Exclusion criteria
* Hypersensitivity to any of the excipients listed in section 6.1 of the abemaciclib (Verzenios) SPC * History of treatment with an anti-CDK4/6 (palbociclib, ribociclib, abemaciclib) for any indication * History of invasive cancer of any histology within the last 2 years, except for superficial skin tumors, not considered to be in complete remission * Presence of functional or inflammatory colorectal disease (Crohn's disease, ulcerative colitis) causing chronic diarrhea (as defined by the WHO as at least 3 bowel movements per day and/or liquid stools for at least 1 month) * Patient who has undergone total gastrectomy or suffers from short bowel syndrome * Patient unable to sign the consent form for societal reasons (illiteracy) or somatic reasons (central nervous system disease). * Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by judicial or administrative decision, persons staying in a health or social care institution, adults under legal protection, and finally patients in emergency situations. * Pregnant or breastfeeding women, women of childbearing age who are not using highly effective contraceptive methods (e.g., double-barrier contraception) during treatment and for at least 3 weeks after stopping treatment (The duration of contraception required for concomitant treatments, if any, should also be taken into account.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the relationship between the probability of occurrence of a severe diarrheal adverse event and plasma exposure to abemaciclib and its metabolites in patients with RH+HER2- breast cancer at high risk of recurrence receiving adjuvant abemaciclib | From enrollment to 6 months of treatment | The probability of severe diarrhea (grades 2, 3, and 4 according to CTCAE v5.0) occurring based on exposure to abemaciclib and its metabolites (M2 and M20) will be characterized by a joint mixed-effects model combining longitudinal, pharmacokinetic (continuous type), and toxicity data (survival type). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine the relationship between the occurrence of severe neutropenic adverse events and plasma exposure to abemaciclib and its metabolites in patients with HR+, HER2- breast cancer at high risk of recurrence who are receiving adjuvant abemaciclib | From enrollment to 6 months of treatment | The probability of severe neutropenia (grades 3 and 4 according to the current CTCAE) occurring based on exposure to abemaciclib and its metabolites (M2 and M20) will be characterized by a joint mixed-effects model combining longitudinal pharmacokinetic (continuous) and pharmacodynamic (neutrophil concentration, continuous) data. pharmacokinetic (continuous type) and pharmacodynamic (concentration of neutrophils, continuous type) data. |
| Develop a joint pharmacokinetic/pharmacodynamic (PK/PD) mixed-effects model that includes data on abemaciclib and metabolite concentrations, neutrophil counts, and severe diarrhea | From enrollment to 6 months of treatment | The mixed-effects PK/PD model was validated using standard diagnostic tools, such as data fit diagnostic plots, visual predictive checks, estimation accuracy, and shrinkage. |
| Evaluate the free fraction (fu) of abemaciclib concentrations at different protocol treatment times in the target population (only at Poitiers University Hospital) | From enrollment to 6 months of treatment | Free concentrations of abemaciclib will only be measured for patients enrolled at Poitiers University Hospital. The "fu" of abemaciclib concentrations will be modeled within the mixed-effects PK/PD model and any correlation with clinical-biological covariates will be evaluated. This exploratory analysis will only be performed on patients enrolled at Poitiers University Hospital for pre-analytical technical reasons. The technique has only been validated on the mass spectrometer in the pharmacology department at Poitiers University Hospital. |
Contacts
CONTACTMatthieu BAINAUD, MD
CONTACTCeline ABONNEAU, Project manager
Outcome results
None listed